A second targeted anticancer drug targeting EGFR Exxon 20 insertion mutation has emerged. Takeda Pharmaceutical Korea announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for the EGFR Exxon 20 insertion mutant non-small cell lung cancer treatment Exkivity (Mobocertinib).

Exkivity is a TKI that inhibits the growth of cancer cells by targeting the EGFR Exxon20 insertion mutation gene. With this permit, Exkivity can be used to treat locally advanced or NSCLC adult patients with EGFR Exxon 20 insertion mutations that have previously been treated with platinum-based chemotherapy. EGFR exon20 insertion mutations are rare, accounting for about 10% of EGFR mutations in n